Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
MindMed to Be Added to the Nasdaq Biotechnology Index
-
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
Explorance Named Gold Winner for AI In Education Award by QS Reimagine Education Awards
-
IAS Announces Exclusive First-to-Market Partnership with Kwai for Business to Provide Content-Level Brand Safety and Suitability Measurement for Advertisers
-
Laser Photonics Wins Dual Order From Phillips 66
-
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
-
Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters
-
Luka Dončić to Launch the Luka Dončić Foundation, Dedicated to Improving Youth Sports
-
Viad Corp to Relaunch as Pursuit and Trade on NYSE as PRSU
-
Kinaxis Announces $40,000 Academic Award to Empower the Next Generation of Supply Chain Innovators
-
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
-
ProPetro Announces Contract for a 4th FORCE® Electric Hydraulic Fracturing Fleet
-
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics
-
NewGen Engages OSL to Execute Strategic Investment in Digital Assets
-
AleAnna Announces Signing of Gas Sale Contract with Shell Energy Europe
-
PyroGenesis Announces Debt-to-Equity Conversion of Client Receivable
-
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
-
Climb Bio to be Added to the Nasdaq Biotechnology Index
-
FactSet Reports Results for First Quarter 2025
-
Tilray Brands, Inc. to Announce Second Quarter Fiscal Year 2025 Financial Results on January 9, 2025
-
Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights
-
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
-
OTC Markets Group Welcomes Metaplanet Inc. to OTCQX
-
Alliance Witan PLC - Net Asset Value
-
Resolutions of the extraordinary general meeting of Enefit Green AS
-
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics
-
Lithium Royalty Corp. Announces US$28 Million Partial Sale of Tres Quebradas Royalty to Triple Flag Precious Metals
-
Triple Flag to Acquire a Royalty on Tres Quebradas
-
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
-
Northisle Announces Final 2024 Drill Results Including 55.8m Grading 2.20 g/t Au and 0.39% Cu
-
Maritime Launch Services Inc. Issues Early Warning Report Filing Pursuant to National Instrument 62-103
-
AECOM to support transformed mobility across Austin, Texas by delivering the city’s first light rail system
-
Alamos Gold Announces Renewal of Normal Course Issuer Bid
-
GOAL BEYOND SCALES BRIDGE PROGRAM TO 850 LEARNERS
-
Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living
-
CarMax Reports Third Quarter Fiscal Year 2025 Results
-
FIGS Announces Updates to Board of Directors
-
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
-
Kimco Realty® Invites You to Join Its Fourth Quarter Earnings Conference Call
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
SIKA AG signs license agreement on Photocat Bitumen technology to combat Air Pollution
-
Valoe Extends the Subscription Period of the Convertible Bond 1/2023
-
Brookdale Improves 2025 Cash Flows by an Expected $15+ Million through Ventas Lease Amendment with Incremental Upside in 2026 and Beyond
-
Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30
-
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults
-
VEON Completes the Move of its Headquarters to Dubai
-
VEON Completes the Move of its Headquarters to Dubai
-
Accenture Reports First-Quarter Fiscal 2025 Results
-
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

